文献速递肾小球疾病

IgA肾病遗传风险评分估算UK Biobank中IgA肾病患病比例

IgA Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in UK Biobank.
PubMed 文献 · Kidney Int Rep · 2020-07-19

研究利用14个SNP构建IgA肾病遗传风险评分(IgAN-GRS),在464例经活检确诊的欧洲IgAN患者中验证,并在379,767名欧洲UKBB参与者中评估。结果显示血尿患者及血尿合并高血压和微量白蛋白尿患者的平均GRS均高于对照,据此估算IgAN分别占非癌症血尿的19%和该三联征的28%。

要点

  • IgAN-GRS在活检确诊IgAN患者中显著高于对照。
  • UKBB血尿患者平均GRS显著高于对照。
  • 估算IgAN占非癌症血尿的19%,占血尿+高血压+微量白蛋白尿的28%。

核心结论

  • IgAN-GRS可无创估算常见表型中IgAN的患病比例。

研究设计与样本

  • 利用14个SNP构建IgAN-GRS,在464例活检确诊欧洲IgAN患者和379,767名欧洲UKBB参与者中验证。

主要发现

  • IgAN队列GRS为4.30(95%CI 4.23-4.38),高于对照的3.98(95%CI 3.97-3.98),P<0.0001。
  • UKBB血尿患者(n=12,858)平均GRS为4.04(95%CI 4.02-4.06),高于对照的3.98(95%CI 3.97-3.98),P<0.0001。
  • 血尿合并高血压和微量白蛋白尿患者(n=1323)平均GRS为4.07(95%CI 4.02-4.13),高于对照的3.98(95%CI 3.97-3.98),P=0.0003。
  • 估算IgAN占非癌症血尿的19%,占血尿合并高血压和微量白蛋白尿的28%。

临床怎么用

  • 多基因风险评分或有助于在大型人群队列中无创识别非特异性肾脏表型的可能病因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: IgA nephropathy (IgAN) is the commonest glomerulonephritis worldwide. Its prevalence is difficult to estimate, as people with mild disease do not commonly receive a biopsy diagnosis. We aimed to generate an IgA nephropathy genetic risk score (IgAN-GRS) and estimate the proportion of people with hematuria who had IgAN in the UK Biobank (UKBB). METHODS: We calculated an IgAN-GRS using 14 single-nucleotide polymorphisms (SNPs) drawn from the largest European Genome-Wide Association Study (GWAS) and validated the IgAN-GRS in 464 biopsy-proven IgAN European cases from the UK Glomerulonephritis DNA Bank (UKGDB) and in 379,767 Europeans in the UKBB. We used the mean of IgAN-GRS to calculate the proportion of potential IgAN in 14,181 with hematuria and other nonspecific renal phenotypes from 379,767 Europeans in the UKBB. RESULTS: The IgAN-GRS was higher in the IgAN cohort (4.30; 95% confidence interval [95% CI: 4.23-4.38) than in controls (3.98; 3.97-3.98; P < 0.0001). The mean GRS in UKBB participants with hematuria (n = 12,858) was higher (4.04; 4.02-4.06) than UKBB controls (3.98; 3.97-3.98; P < 0.0001) and higher in those with hematuria, hypertension, and microalbuminuria (n = 1323) (4.07; 4.02-4.13) versus (3.98; 3.97-3.98; P = 0.0003). Using the difference in these means, we estimated that IgAN accounted for 19% of noncancer hematuria and 28% with hematuria, hypertension, and microalbuminuria in UKBB. CONCLUSIONS: We used an IgAN-GRS to estimate the prevalence of IgAN contributing to common phenotypes that are not always biopsied. The noninvasive use of polygenic risk in this setting may have further utility to identify likely etiology of nonspecific renal phenotypes in large population cohorts.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Sukcharoen K, Sharp SA, Thomas NJ, et al. IgA Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in UK Biobank. Kidney Int Rep. 2020. PMID: 33102956. doi:10.1016/j.ekir.2020.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。